Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study

Bernhard Ziegler, Mirjam Bachler, Hubert Haberfellner, Christian Niederwanger, Petra Innerhofer, Tobias Hell, Marc Kaufmann, Marc Maegele, Uriel Martinowitz, Carolin Nebl, Elgar Oswald, Herbert Schöchl, Bettina Schenk, Markus Thaler, Benjamin Treichl, Wolfgang Voelckel, Ivana Zykova, Christine Wimmer, Dietmar Fries, FIinTIC study group, Bernhard Ziegler, Mirjam Bachler, Hubert Haberfellner, Christian Niederwanger, Petra Innerhofer, Tobias Hell, Marc Kaufmann, Marc Maegele, Uriel Martinowitz, Carolin Nebl, Elgar Oswald, Herbert Schöchl, Bettina Schenk, Markus Thaler, Benjamin Treichl, Wolfgang Voelckel, Ivana Zykova, Christine Wimmer, Dietmar Fries, FIinTIC study group

Abstract

Background: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients.

Objective: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed.

Design: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial.

Setting: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015.

Patients: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo.

Interventions: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre.

Main outcome measures: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug.

Results: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period.

Conclusion: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability.

Trial registry numbers: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society of Anaesthesiology.

Figures

Fig. 1
Fig. 1
Patient disposition
Fig. 2
Fig. 2
Values at baseline (T1) and emergency room admission (T2), and the differences between these timepoints, in selected ROTEM parameters
Fig. 3
Fig. 3
Changes in FIBTEM maximum clot firmness (FIBTEM MCF) between baseline (T1) and 7 days posttrauma (T7)

References

    1. Maegele M, Lefering R, Yucel N, et al. . Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38:298–304.
    1. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360–365.
    1. Inaba K, Karamanos E, Lustenberger T, et al. . Impact of fibrinogen levels on outcomes after acute injury in patients requiring a massive transfusion. J Am Coll Surg 2013; 216:290–297.
    1. Rourke C, Curry N, Khan S, et al. . Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10:1342–1351.
    1. McQuilten ZK, Wood EM, Bailey M, et al. . Fibrinogen is an independent predictor of mortality in major trauma patients: a five-year statewide cohort study. Injury 2017; 48:1074–1081.
    1. Nakamura Y, Ishikura H, Kushimoto S, et al. . Fibrinogen level on admission is a predictor for massive transfusion in patients with severe blunt trauma: analyses of a retrospective multicentre observational study. Injury 2017; 48:674–679.
    1. Hagemo JS, Christiaans SC, Stanworth SJ, et al. . Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: an international prospective validation study. Crit Care 2015; 19:97.
    1. Veigas PV, Callum J, Rizoli S, et al. . A systematic review on the rotational thrombelastometry (ROTEM() values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients. Scand J Trauma Resusc Emerg Med 2016; 24:114.
    1. Innerhofer P, Fries D, Mittermayr M, et al. . Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4:e258–e271.
    1. Schochl H, Nienaber U, Maegele M, et al. . Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83.
    1. Nascimento B, Callum J, Tien H, et al. . Fibrinogen in the initial resuscitation of severe trauma (FiiRST): a randomized feasibility trial. Br J Anaesth 2016; 117:775–782.
    1. Yamamoto K, Yamaguchi A, Sawano M, et al. . Preemptive administration of fibrinogen concentrate contributes to improved prognosis in patients with severe trauma. Trauma Surg Acute Care Open 2016; 1:e000037.
    1. Mengoli C, Franchini M, Marano G, et al. . The use of fibrinogen concentrate for the management of trauma-related bleeding: a systematic review and meta-analysis. Blood Transfus 2017; 15:318–324.
    1. Maegele M, Zinser M, Schlimp C, et al. . Injectable hemostatic adjuncts in trauma: fibrinogen and the FIinTIC study. J Trauma Acute Care Surg 2015; 78:S76–82.
    1. Spahn DR, Bouillon B, Cerny V, et al. . The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019; 23:98.
    1. Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006; 16:773–776.
    1. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. . Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7:795–802.
    1. Schochl H, Cotton B, Inaba K, et al. . FIBTEM provides early prediction of massive transfusion in trauma. Crit Care 2011; 15:11.
    1. Martini WZ, Guzman R, Dubick MA. Stability of fibrinogen concentrate in human blood samples: an in vitro study. Mil Med 2018; 183:183–188.
    1. Curry N, Foley C, Wong H, et al. . Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multicentre, randomised, double blind, placebo-controlled pilot trial. Crit Care 2018; 22:164.
    1. Holcomb JB, Weiskopf R, Champion H, et al. . Challenges to effective research in acute trauma resuscitation: consent and endpoints. Shock 2011; 35:107–113.
    1. Schlimp CJ, Ponschab M, Voelckel W, et al. . Fibrinogen levels in trauma patients during the first seven days after fibrinogen concentrate therapy: a retrospective study. Scand J Trauma Resusc Emerg Med 2016; 24:29.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj